People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| StrideBio, Inc. | — | Biotechnology | Series C | $57.7M | $1.5B | 2018 |
| Ribometrix, Inc. | — | Pharmaceuticals | Series A | $18.5M | $464.6M | 2017 |
Mike Dial at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mike Dial on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Joshua Resnick | 1 | 12 |
| Richard Smith | 1 | 11 |
| Michael Martin | 1 | 11 |
| Clay Thorp | 1 | 10 |
| Michael Solomon | 1 | 7 |
| William Marshall | 1 | 6 |
| Robert Hughes | 1 | 6 |
| Shaan Gandhi | 1 | 4 |
| Karen Hong | 1 | 4 |
| Sapan Shah | 1 | 4 |
| Michael Dial | 1 | 4 |
| Erica Whittaker | 1 | 3 |
| JOHN GUSTOFSON | 1 | 3 |
| Hakan Goker | 1 | 2 |
| Stewart Parker | 1 | 2 |
| Patrick Ritschel | 1 | 2 |
| Aravind Asokan | 1 | 1 |
| Mavis Agbandje-McKenna | 1 | 1 |
| Mavis Abjandje-McKenna | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.